Medicare begins coverage of GLP-1 medications for obesity July 7, 2026 Summary: Starting July 1, 2026, Medicare beneficiaries can access GLP-1 obesity drugs for a flat $50 monthly copay through the CMS Bridge demonstration, an 18-month, taxpayer-funded stopgap created after private insurers balked at the original BALANCE model
58.6% of people on the 12 mg dose lost at least 25% of their body weight
GLP-1s currently are taken in injections, but Eli Lilly is asking for Food and Drug Administration approval for a pill, orforglipron, that it has agreed to price at $149 for the lowest dose, and $399 for other doses
The ordering process Once a prescription reaches Red Rock, the typical workflow looks like this
Green offers many treatment options, including PRP infusions to strengthen hair follicles and promote hair growth, as well as prescription medications such as minoxidil and finasteride
For people with obesity who havent succeeded with lifestyle interventions alone, it offers a powerful tool that works through biological mechanisms, not willpower